GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Cyclically Adjusted Price-to-FCF

Mabion (WAR:MAB) Cyclically Adjusted Price-to-FCF : (As of May. 09, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Mabion Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mabion Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Mabion's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Cyclically Adjusted Price-to-FCF Chart

Mabion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mabion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mabion's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Mabion's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabion's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Mabion's Cyclically Adjusted Price-to-FCF falls into.


;
;

Mabion Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Mabion's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Mabion's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.175/153.4391*153.4391
=-0.175

Current CPI (Sep. 2024) = 153.4391.

Mabion Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -1.364 100.122 -2.090
201503 -0.654 100.041 -1.003
201506 -0.738 100.448 -1.127
201509 -3.642 99.634 -5.609
201512 -0.887 99.471 -1.368
201603 -0.211 98.983 -0.327
201606 -1.574 99.552 -2.426
201609 -0.331 99.064 -0.513
201612 0.774 100.366 1.183
201703 -1.199 101.018 -1.821
201706 -1.207 101.180 -1.830
201709 -1.818 101.343 -2.753
201712 -0.970 102.564 -1.451
201803 -1.661 102.564 -2.485
201806 -1.302 103.378 -1.932
201809 0.021 103.378 0.031
201812 -0.689 103.785 -1.019
201903 -1.256 104.274 -1.848
201906 -0.666 105.983 -0.964
201909 -0.459 105.983 -0.665
201912 -0.751 107.123 -1.076
202003 -0.842 109.076 -1.184
202006 -0.491 109.402 -0.689
202009 -0.801 109.320 -1.124
202012 -0.674 109.565 -0.944
202103 1.051 112.658 1.431
202106 -3.114 113.960 -4.193
202109 0.514 115.588 0.682
202112 -2.572 119.088 -3.314
202203 -1.861 125.031 -2.284
202206 0.310 131.705 0.361
202209 -0.378 135.531 -0.428
202212 3.394 139.113 3.744
202303 1.018 145.950 1.070
202306 -1.879 147.009 -1.961
202309 -0.357 146.113 -0.375
202312 -1.275 147.741 -1.324
202403 0.926 149.044 0.953
202406 1.448 150.997 1.471
202409 -0.175 153.439 -0.175

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mabion  (WAR:MAB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Mabion Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Mabion's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabion Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
N/A
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion Headlines